Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor α-like ligand 1A (TL1A)
- Target
- TL1A
- Molecular classification
- Tumor necrosis factor superfamily ligand, Type II transmembrane protein, Cytokine
01
Overview
Tumor necrosis factor α-like ligand 1A (TL1A) is a member of the tumor necrosis factor superfamily (TNFSF15). It functions as a costimulatory signal for activated lymphocytes, particularly gut-specific CD4+ T cells, influencing Th1, Th2, and Th17 responses. TL1A interacts with its signaling receptor, Death Receptor 3 (DR3), to promote inflammation and fibrosis in autoimmune diseases like inflammatory bowel disease (IBD). Decoy Receptor 3 (DcR3) can bind TL1A and inhibit DR3 signaling. TL1A is considered a therapeutic target for chronic inflammatory conditions.
- Other names
- TNF-like cytokine 1ATNFSF15VEGIVascular endothelial growth inhibitor
02
Mechanism of action
Blockade of TL1A or its receptor DR3 to reduce inflammation and fibrosis
03
Biological functions
Immune cell costimulationRegulation of mucosal immunityT cell differentiationNF-kB activationMAPK pathway activation
04
Disease associations
Inflammatory bowel disease (IBD)Crohn's diseaseUlcerative colitisRheumatoid arthritisPsoriatic arthritisAnkylosing spondylitisAutoimmune diseases
05
Safety considerations
Potential for immunosuppressionImpaired mucosal defense mechanismsExtraintestinal manifestations
06
Biomarkers
TL1A levels in inflamed tissuesGenetic polymorphisms in TNFSF15
Beyond the preview
Go deeper on Tumor necrosis factor α-like ligand 1A (TL1A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor necrosis factor α-like ligand 1A (TL1A).